Vinati Organics Q4 FY26: Profit up, ₹360 cr capex plan

Key takeaway for investors

Vinati Organics Ltd reported stronger profitability in Q4 FY26, aided by margin expansion and operational execution, even as revenue numbers varied across reported snapshots. Management also reiterated a capacity and product innovation push, including investments of about ₹360 crore in FY26. Demand trends were discussed across key product lines such as ATBS and butyl phenols, while the IBB segment was flagged as a challenge area. The company’s commentary points to a focus on cost discipline, passing through raw material inflation where possible, and scaling newer opportunities like antioxidants.

What management said on CNBC-TV18 (May 14, 2026)

In a CNBC-TV18 interview dated May 14, 2026, Managing Director and CEO Vinati Saraf Mutreja discussed the company’s Q4 and full-year FY26 performance. She attributed profit improvement primarily to margin expansion, while also noting ongoing input cost pressures. She also pointed to strong demand in the ATBS and butyl phenol segments, alongside issues in the IBB segment. Separately, the company indicated it is investing about ₹360 crore in FY26 to build capacity and develop new products, with a stated focus on the antioxidants space.

Q4 FY26 results announcement and the headline numbers (May 12, 2026)

Vinati Organics’ Q4 FY26 results were reported as having been announced on May 12, 2026, for the quarter ended March 31, 2026. One reported set of numbers showed consolidated net profit at ₹123.86 crore, up 23% year-on-year from ₹100.83 crore in Q4 FY25. In the same snapshot, revenue from operations was reported at ₹624.31 crore, up 16% year-on-year. Sequentially, this snapshot showed total income rising to ₹624.31 crore from ₹539.64 crore in Q3 FY26, while PAT rose to ₹123.86 crore from ₹100.83 crore.

Another reported print: ₹500.65 crore quarterly revenue

A separate reported dataset quoted Q4 FY26 revenue at ₹500.65 crore and net profit at ₹150.24 crore. The same source also stated full-year FY26 consolidated revenue at ₹2,185.87 crore and consolidated net profit at ₹651.67 crore. These figures were presented in the context of the May 14 management interview. Since the provided material contains multiple reported values for the same period, the numbers are best read as different reporting snapshots rather than a single consolidated view.

Segment demand: ATBS, butyl phenols, and the IBB challenge

The provided information indicates strong demand in ATBS (Acrylamido Tertiary Butyl Sulfonic Acid) and butyl phenol segments. At the same time, the IBB segment was described as facing challenges, with production issues mentioned and expected to be resolved. Management positioning in this context was that once operational issues stabilise, the company expects to capture growing domestic demand and expand market share. The material also mentions improved pricing power and volume expansion as drivers supporting revenue and profitability.

Antioxidants: 70% revenue growth cited

The antioxidants segment was specifically highlighted as a growth driver, with 70% revenue growth cited. The company’s investment and innovation focus was stated to be “particularly in the antioxidants sector,” alongside broader capacity enhancement plans. This emphasis matters because antioxidants demand is linked to downstream industrial cycles, and the company appears to be aligning capital allocation with higher-growth product opportunities.

Capex and growth outlook: ₹360 crore and a 20% CAGR aspiration

The company is said to be investing approximately ₹360 crore in FY26 toward capacity additions and new product development. The provided material also cites an “anticipated 20% CAGR in revenue over the next three years,” linked to a positive market outlook, particularly from the oil and gas sector. Separately, a management guidance point in the text mentions ~15% volume growth in FY27, with EBITDA margins expected to remain in the ~26%-27% range. Input costs were flagged as a continuing challenge, with an expectation that cost increases may be passed on to customers.

Market impact and what to watch

For investors tracking specialty chemicals, the key market variables referenced here are demand trends in ATBS and butyl phenols, the pace of recovery in the IBB segment, and the company’s ability to defend margins amid raw material cost pressure. Multiple reported revenue prints for Q4 FY26 also mean investors may focus on the company’s final audited disclosures and consistent presentation in subsequent filings. Operationally, production normalisation in challenged segments can influence volumes, while new capacity and product launches can change the growth mix over the next few quarters.

Summary table of reported figures (all values in ₹ crore)

Why the story matters (analysis)

Vinati Organics’ Q4 FY26 narrative, as presented, is primarily about protecting profitability through margins and execution while managing segment-specific volatility. The repeated references to operational efficiency, disciplined cost management, and pass-through of input costs highlight how chemical companies defend earnings when raw material prices fluctuate. The stated investment plan and focus on antioxidants suggests a strategy to broaden growth drivers beyond the core product set. Finally, the oil and gas-linked demand outlook and the emphasis on domestic demand indicate that end-market cycles, not just capacity, will shape near-term performance.

Conclusion

Vinati Organics reported improved Q4 FY26 profitability and laid out a ₹360 crore FY26 investment plan alongside commentary on strong ATBS and butyl phenol demand and challenges in IBB. The next key checkpoints will be follow-up disclosures on capacity execution, segment recovery, and how margins hold up amid input cost pressure.